

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 July 2024 (11.07.2024)



(10) International Publication Number
WO 2024/146536 A1

(51) International Patent Classification:

C07K 16/30 (2006.01) A61K 47/64 (2017.01)
C12P 21/08 (2006.01) A61K 39/395 (2006.01)
C12N 15/62 (2006.01)

(21) International Application Number:

PCT/CN2024/070253

(22) International Filing Date:

03 January 2024 (03.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/070283
04 January 2023 (04.01.2023) CN
PCT/CN2023/082744
21 March 2023 (21.03.2023) CN

(71) Applicant: **BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.** [CN/CN]; No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN).

(72) Inventors: **ZHANG, Yifu**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN). **SHANG, Chengzhang**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN). **YANG, Yi**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN). **SHEN, Yuele**; No.12,

Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-MUC1 ANTIBODIES AND USES THEREOF




FIG. 1

(57) Abstract: Provided are anti-MUC1 (Mucin 1, cell surface associated) antibodies, antigen-binding fragments thereof, antibody-drug conjugate (ADC) derived therefrom, and the uses thereof.

WO 2024/146536 A1